British FTSE 100 pharmaceutical company AstraZeneca has received regulatory approval to start the third stage of its trial for a Covid-19 vaccine in Russia.
According to a filing in the Russian registry of clinical trials on 21 August, as reported by Reuters, the vaccine will be tested on 150 participants. The trial will be managed by four medical facilities in St. Petersburg and Moscow. The AZD1222 vaccine was co-invented by the University of Oxford and its spin-out company, Vaccitech.
